Compare Enveric Biosciences Inc (ENVB) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ProShares UltraPro QQQ ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $5.32M), while ProShares UltraPro QQQ ETF trades at $72.56. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | TQQQ | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $17.40 | $87.22 |
52-Week Low | $1.28 | $37.89 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $71.23, down 5.05% amid a bearish technical signal. The fund lacks traditional valuation ratios like P/E or P/B as it is structured to deliver daily leveraged returns, not company earnings. Recent news highlights concerns over volatility and hidden costs in leveraged ETFs, with Warren Buffett criticizing the 'gambling mood' around such products (CNBC, May 2, 2026).
The outlook for TQQQ is highly volatile, offering amplified gains in bull markets but severe losses during downturns, as seen in its 81% drop in 2022. Risks include daily rebalancing costs and market volatility amplification. Investors require strong conviction in Nasdaq-100 rallies and risk tolerance for sharp drawdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
